

SUMMARY PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Hydralazine Hydrochloride Injection USP 20mg/ml

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml Contains

Hydralazine Hydrochloride.....20 mg

Excipients of known effect:

Each mL contains:

Methylparaben.....0.65 mg

Propylparaben.....0.35 mg

Propylene Glycol.....103.6 mg

3. PHARMACEUTICAL FORM

Solution for Injection.

Clear colorless Solution filled in Amber Color glass ampoules properly sealed and labelled

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

In the treatment of hypertensive emergencies, including pre-eclampsia and toxemia of pregnancy, and in hypertension with renal complications.

4.2 Posology and method of administration

Adults:

Hypertension: The dose should be adjusted to the individual requirements of the patient. Treatment should begin with low doses of Hydralazine which, depending on the patient's response should be increased stepwise to achieve optimal therapeutic effect whilst keeping unwanted effects to a minimum.

Paediatric population

Not recommended

Use in the elderly

Clinical evidence would indicate that no special dosage regimen is necessary but concurrent hepatic and renal insufficiency should be taken into account.

Method of administration:

Parenteral: Initially 5 to 10 mg by slow intravenous injection, to avoid precipitous decreases in arterial pressure with a critical reduction in cerebral or utero-placental perfusion. If necessary a repeat injection can be given after an interval of 20-30 minutes, throughout which blood pressure and heart rate should be monitored. A satisfactory response can be defined as a decrease in diastolic blood pressure to 90/100 mm Hg. The contents of the vial should be reconstituted by dissolving in 1ml of Water for Injection. This should then be further diluted with 10 ml of Sodium Chloride Injection 0.9% and be administered by slow intravenous injection. The injection must be given immediately and any remainder discarded.

Hydralazine may also be given by continuous intravenous infusion, beginning with a flow rate of 200-300 microgram/minute. Maintenance flow rates must be determined individually and are usually within the range 50-150 microgram/minute. The product reconstituted as for direct iv injection may be added via the infusion container to 500 millilitre of Sodium Chloride Injection 0.9% and given by continuous infusion. The addition should be made immediately before administration and the mixture should not be stored. Hydralazine for infusion can also be used with 5% sorbitol solution or isotonic inorganic infusion solutions such as Ringer's solution.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Severe tachycardia and heart failure with a high cardiac output (e.g. in thyrotoxicosis). Myocardial insufficiency due to mechanical obstruction (e.g. aortic or mitral stenosis or constrictive pericarditis).

Idiopathic systemic lupus erythematosus (SLE) and related diseases.

Isolated right ventricular failure due to pulmonary hypertension (cor pulmonale).

Dissecting aortic aneurysm.

4.4 Special warnings and precautions for use**Warnings**

The overall state of the circulation induced by hydralazine may accentuate certain clinical conditions. Myocardial stimulation may provoke or aggravate uncontrolled or untreated angina pectoris. Therefore, Hydralazine should only be given to patients with suspected or confirmed coronary artery disease who are already being treated with a β -blocker, or in combination with other suitable sympatholytic

agents. It is important that the β -blocker medication should be commenced a few days before the start of treatment with Hydralazine.

Patients who have survived a myocardial infarction should not receive Hydralazine until a post-infarction stabilisation phase has been achieved.

Prolonged treatment with hydralazine (ie, usually treatment for more than 6 months) may provoke a systemic lupus erythematosus (SLE)-like syndrome, especially where dosages exceeding 100 mg daily are prescribed. In its mild form this syndrome is reminiscent of rheumatoid arthritis (arthralgia, sometimes associated with fever, anaemia, leucopenia, thrombocytopenia and skin rash) and proves reversible after withdrawal of the drug. In its more severe form it resembles acute SLE (similar manifestations as the milder form, plus pleurisy, pleural effusions and pericarditis; whereas nervous system and renal involvement are more rare than in idiopathic lupus). Early detection and a timely diagnosis with appropriate therapy (i.e. treatment discontinuation and possibly long-term treatment with corticosteroids) are of utmost importance in this life-threatening illness to prevent more severe complications, which may sometimes be fatal.

In particular, renal symptoms are less frequent than in idiopathic SLE and pleuro-pulmonary symptoms, as well as pericarditis, are more frequent.

Since such reactions tend to occur more frequently the higher the dose and the longer its duration, and since they are also more common in slow acetylators, it is recommended that for maintenance therapy the lowest effective dose should be used. If 100 mg daily fails to elicit an adequate clinical effect, the patient's acetylator status should be evaluated. Slow acetylators and women run a greater risk of developing the SLE-like syndrome and every effort should therefore be made to keep the dosage below 100 mg daily and a careful watch kept for signs and symptoms suggestive of this syndrome. If such symptoms do develop the drug should be gradually withdrawn. Rapid acetylators often respond inadequately even to doses of 100 mg daily and therefore the dose can be raised with only a slightly increased risk of a SLE-like syndrome.

During long-term treatment with Hydralazine it is advisable to determine the antinuclear factors (ANF) and to carry out urine analyses at intervals of approx. 6 months. Microhaematuria and/or proteinuria, in particular together with positive titres of ANF, may be initial signs of immune-complex glomerulonephritis associated with the SLE-like syndrome. If overt clinical signs and symptoms develop, the drug should be withdrawn at once.

Precautions

Isolated cases of peripheral neuritis have been reported. Published evidence suggests an antipyridoxine effect, which may respond to pyridoxine administration or drug withdrawal.

Laboratory tests: A complete blood count and ANF titre determination is indicated before and periodically during prolonged therapy with hydralazine even if the patient is asymptomatic. These studies are also indicated if the patient develops arthralgia, fever, chest pain, persistent malaise, or other unexplained signs or symptoms. A positive ANF titre requires that the physician carefully weighs the implications of the test results against the benefits of continued therapy with hydralazine.

Adverse haematological effects, such as a reduction in haemoglobin and red cell count, leucopenia, agranulocytosis and purpura, have been reported in a very few cases. If such abnormalities develop, therapy should be discontinued.

Hydralazine can cause anginal attacks and ECG changes indicative of myocardial ischaemia. It must therefore be used with caution in patients with suspected coronary artery disease.

In patients with moderate to severe renal impairment (creatinine clearance < 30 ml/min or serum creatinine concentrations > 2.5 mg/100 ml or 221 micromol/l) and in patients with hepatic dysfunction the dose or interval between doses should be adjusted according to clinical response, in order to avoid accumulation of the "apparent" active substance (see 4.2 Posology and method of administration, and 4.3 Contraindications).

Like all potent antihypertensives, Hydralazine should be used with caution in patients with coronary artery disease or acute cerebrovascular disease, since it enhances the cardiac-enhancing effects of hydralazine.

In patients undergoing surgery whilst being treated with Hydralazine a fall in blood pressure may occur. Adrenaline should not be used to correct the hypertension as it enhances the cardiac-accelerating effects of hydralazine.

Treatment with hydralazine may induce systemic vasculitis, including ANCA(+) vasculitis, leading to pulmonary renal syndrome which is a combination of diffuse alveolar haemorrhage and rapidly progressive glomerulonephritis. Patients may present with severe respiratory and/or renal failure and require treatment in an intensive care unit. The syndrome is characterized by a fulminant course if left untreated and may sometimes be fatal.

Oral forms only

When initiating therapy in heart failure, particular caution should be exercised and the patient kept under surveillance and/or haemodynamic monitoring for early

detection of postural hypotension or tachycardia. Where discontinuation of therapy in heart failure is indicated, Hydralazine should be withdrawn gradually (except in serious situations, such as SLE-like syndrome or blood dyscrasias) in order to avoid precipitation and/or exacerbation of heart failure.

4.5 Interaction with other medicinal products and other forms of interaction

The effects of this preparation are potentiated by other anti-hypertensive drugs, diuretics, alcohol, anaesthetics, tricyclic antidepressants, major tranquilisers or drugs exerting a central depressant action. This should be borne in mind when relevant concomitant therapy is being considered.

This product should be used with caution in patients taking MAO inhibitors.

Administration of Hydralazine shortly before or after diazoxide may give rise to marked hypotension.

Concurrent administration of Hydralazine with beta-blockers subject to a strong first-pass effect (e.g. propranolol) may increase their bioavailability. Downward adjustment of these drugs may be required when they are given concomitantly with Hydralazine.

4.6 Fertility, pregnancy and lactation

Pregnancy

No serious adverse effects in human pregnancy have been observed to date with Hydralazine, although experience in the third trimester is extensive. However, animal experiments have shown teratogenic potential in mice but not in other animal species. Hydralazine crosses the placenta. Use of Hydralazine in pregnancy, before the third trimester should be avoided, but the drug may be employed in later pregnancy if there is no safer alternative or when the disease itself carries serious risks for the mother or child, eg pre-eclampsia and/or eclampsia.

Breast-feeding

Hydralazine passes into breast milk but reports available so far have not shown adverse effects on the infant. Mothers in whom use of Hydralazine proves unavoidable may breast feed their infant provided that the infant is observed for possible adverse effects.

4.7 Effects on ability to drive and use machines

Hydralazine has minor influence on the ability to drive and use machines.

Hydralazine may impair the patient's reactions, especially at the start of treatment and the patient should be warned of the hazard when driving or operating machinery.

4.8 Undesirable effects

The information below lists reported adverse reactions, ranked using the following frequency classification: Very common (2/1/10); common (2/1/100 to <1/10);

uncommon (2'1/1,000 to <1/100); rare (2'1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Some of the adverse effects listed below e.g. tachycardia, palpitation, anginal symptoms, flushing, headache, dizziness, nasal congestion and gastrointestinal disturbances are commonly seen at the start of treatment, especially if the dose is raised quickly. However, such effects generally subside in the further course of treatment.

System Class	Organ	Frequency	Adverse effects
Blood and lymphatic system disorders		Uncommon	anaemia, leucopenia, neutropenia, thrombocytopenia with or without purpura
		Very rare	Haemolytic anaemia, leukocytosis, lymphadenopathy, pancytopenia, splenomegaly, agranulocytosis
Immune system disorders		Not known	vasculitis including pulmonary renal syndrome
		Common	SLE-like syndrome (sometimes resulting in a fatal outcome)
		Uncommon	hypersensitivity reactions such as pruritus, urticaria, vasculitis, eosinophilia. hepatitis
Psychiatric disorders		Uncommon	agitation, anorexia, anxiety.
		Very rare	Depression, hallucinations
Nervous system disorders		Very common	Headache
		Uncommon	dizziness
		Very rare	peripheral neuritis polyneuritis, paresthesia (these unwanted effects may be reversed by administering pyridoxine), and tremor
Eye disorders		Uncommon	increased lacrimation, conjunctivitis
		Very Rare	exophthalmos
Cardiac disorders		Very common	tachycardia, palpitation
		Common	flushing, hypotension, anginal symptoms
		Uncommon	oedema, congestive heart failure
		Very Rare	paradoxical pressor responses.

Respiratory, thoracic and mediastinal disorders	Uncommon	dyspnoea, pleural pain, nasal congestion
Gastrointestinal disorders	Common	gastro-intestinal disturbances, diarrhoea nausea, vomiting
	Uncommon	jaundice, liver enlargement. abnormal liver function sometimes in association with hepatitis
	Very Rare	paralytic ileus
Skin and subcutaneous tissue disorders	Uncommon	rash
Musculoskeletal and connective tissue disorders	Common	arthralgia, joint swelling. myalgia
Renal and urinary disorders	Uncommon	proteinuria, increased plasma creatinine, hematuria sometimes in association with glomerulonephritis
	Very Rare	acute renal failure, urinary retention fever
General disorders and administration site conditions	Uncommon	fever, weight decrease. malaise

Reporting of adverse Effects

Healthcare professionals are requested to report any suspected adverse reactions via the Pharmacy and Poisons Reporting System (PvERS) <https://pv.pharmacyboardkenya.org>

4.9 Overdose

Symptoms:

Symptoms include hypotension, tachycardia, myocardial ischaemia, dysrhythmias and coma. Supportive measures, including intravenous fluids are indicated.

Management:

Gastric lavage should be instituted as soon as possible. Supportive measures, including intravenous fluids are also indicated. If hypotension is present, an attempt should be made to raise the blood pressure without increasing the tachycardia. Adrenaline should therefore be avoided.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: vasodilator and antihypertensive agent

ATC Code: C02DB02

Mechanism of action:

Hydralazine is a direct acting vasodilator, which exerts its effects principally on the arterioles. Its precise mode of action is not known.

Pharmacodynamic effects:

Administration of hydralazine produces a fall in peripheral resistance and a decrease in arterial blood pressure, effects which induce reflex sympathetic cardiovascular responses. The concomitant use of a beta-blocker will reduce these reflex effects and enhance the anti-hypertensive effect. The use of hydralazine can result in sodium and fluid retention, producing oedema and reduced urinary volume. These effects can be prevented by concomitant administration of a diuretic.

5.2 Pharmacokinetic properties

Absorption:

Local arteriolar vasodilator, well absorbed and subject to a dose-dependant first pass effect (bioavailability 26-55%) depending on individual acetylator status.

Distribution:

Peak plasma concentrations are attained after 0.5 to 1.5 hours. Plasma $T_{1/2}$ averages 2-3 hours but is prolonged up to 16 hours in severe renal failure (creatinine clearance less than 20 ml/min) and is shortened to approximately 45 mins in rapid acetylators. Hydralazine is rapidly distributed in the body and displays a particular affinity for the blood-vessel walls. Plasma protein binding is in the order of 90%.

Biotransformation:

Hydralazine appears in the plasma chiefly in the form of a readily hydrolysable conjugate with pyruvic acid.

Elimination:

Excretion is mainly through kidney as acetylated and hydroxylated metabolites, some of which are conjugated with glucuronic acid.

5.3 Preclinical safety data

In lifetime carcinogenicity studies, hydralazine caused small but statistically significant increases in lung tumours in mice and hepatic and testicular tumours in rats, towards the end of the experiments.

A mutagenic potential in bacterial test systems was noted, but the significance of this is unclear. Many years of international use have not implied an association of hydralazine with human cancer.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Water for Injection
Methyl paraben
Propyl Paraben
Propylene Glycol

6.2 Incompatibilities

HYDRAGOOD should not be diluted.

6.3 Shelf life

36 months.

6.4 Special precautions for storage

Store below 30°C. Protect from light and moisture.
Keep medicines out of reach of children.

6.5 Nature and contents of container

5 x 2 ml Amber Ampoule packed in carton with leaflet and transparent plastic tray.

6.6 Special precautions for disposal and other handling

No special requirements

7. MARKETING AUTHORISATION HOLDER AND MANUFACTURER

Marketing Authorisation Holder:

GOODMED HEALTHCARE LTD
P.O BOX 76337,
NAIROBI, KENYA

Manufactured by:

Om Biomedic Pvt. Ltd. (WHO GMP Certified Company)
Plot No. 68, 69, 82883, Sector-6A,
IIE SIDCUL, Haridwar-249403 (UK),

India.

8. MARKETING AUTHORIZATION NUMBER:

H2025/CTD12046/26276

9. DATE OF FIRST REGISTRATION / RENEWAL OF THE REGISTRATION

27/08/2025

10. Date of Revision of the Text:

03/2021